Wei Tang

ACEA Therapeutics Inc.

San Diego, CA

United States

SCHOLARLY PAPERS

1

DOWNLOADS

69

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

Number of pages: 37 Posted: 28 Jan 2019
Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 69 (603,647)

Abstract:

Loading...

Abivertinib, resistance, EGFR amplification